shavemyfurm

shavemyfurm | Joined since 2020-11-23

Investing Experience -
Risk Profile -

Followers

0

Following

0

Blog Posts

0

Threads

534

Blogs

Threads

Portfolio

Follower

Following

Summary
Total comments
534
Past 30 days
0
Past 7 days
0
Today
0

User Comments
Stock

2021-08-03 18:38 | Report Abuse

Self talking seems happy to them ? Syiok sendiri.

Stock

2021-08-03 18:15 | Report Abuse

@MadCow75
they failed to hit KPI, boss scold aldi - open more account, copy paste more.
The boss will pay more to them.

Stock

2021-08-03 18:13 | Report Abuse

Seems all this new account so working hard now. OT for extra money .
Everyday, never missed.

Stock
Stock

2021-08-02 11:25 | Report Abuse

Invest BIOALPHA HOLDINGS ?
Ini kalilah !!!

Stock

2021-08-02 11:23 | Report Abuse

Guess kanger x Sinopharm will booming soon.

BEIJING (China Daily/ANN): Sinopharm's Covid-19 vaccine has been approved for emergency use for young people ages 3 to 17, after early and midstage clinical trials showed it is safe and can elicit strong immune responses in the age group, the company said in a recent statement.

The approval was granted by the Joint Prevention and Control Mechanism of the State Council, which was set up to deal with the Covid-19 pandemic.

It is the second domestic Covid-19 vaccine made available for children and teenagers in China. In June, Sinovac Biotech's vaccine was authorised for emergency use for young people.

Sinopharm said in a statement released on Friday that it had completed the first and second stages of clinical trials in Henan province on people ages 3 to 17, which showed their vaccine was effective and safe.

All trial participants had generated antibodies to tackle the virus after receiving two doses. There were no significant differences in the strength of their immunity when compared with adult counterparts.

The vaccine showed good safety and no severe adverse effects had been recorded, the company said.

"We began clinical trials among adolescents by first testing 13- to 17-year-olds, then proceeding to 6-to 12-year-olds and 3- to 5-year-olds, so as to guarantee safety," said Zhang Yuntao, chief scientist and vice-president of Sinopharm's China National Biotech Group, during an interview with China National Radio.

The company said it also launched a study in Abu Dhabi in the United Arab Emirates on June 6, to evaluate the vaccine's efficacy in a group of 900 people of different nationalities ages 3 to 17.

Vaccinating children and teens is essential to building an immunity barrier against the virus, Zhang said. Young people's immune systems are still developing, so researchers are careful when involving them in clinical trials, he said.

Zhang said it will likely take another year for the vaccine to receive full market approval from the nation's top drug regulator for use in younger people.

Sinovac also reported encouraging results from the first and second stage clinical trials of its vaccine on 552 people ages 3 to 17 in Hebei province, conducted from October to December.

According to results published in The Lancet medical journal in late June, its vaccine had elicited antibody responses in over 96 per cent of trial participants, on par with the rate in trials involving adults.

Liu Peicheng, a spokesman for Sinovac, said the vaccines administered to children and teens are identical to those delivered to adults.

"There is no need to take extra precautions when inoculating children," he added.

Last week, several cities in the Guangxi Zhuang autonomous region and Fujian and Hebei provinces announced they will begin administering Covid-19 vaccines to teenagers ages 12 to 17, with some cities saying they will complete the inoculations by the end of September or October.

Since then, more than a dozen provincial-level regions have announced similar plans.

Beijing is taking surveys and rolling out publicity campaigns in preparation for the start of its vaccination programme for teenagers after September, community workers told the newspaper Health Times. - China Daily/Asia News Network

Stock

2021-07-30 14:08 | Report Abuse

@BilisMasin Lazy keyboard warrior, hit KPI then off PC go sleep.
Morning no wake up. How you investing stock oh. No wonder you lose money. Aiya , then you cannot blame, because you totally don't know what is happening

Stock

2021-07-30 14:06 | Report Abuse

hahahaha, I am not 18K, not olangbolo , but they are my multiple account, we take turn comment. later they combo for sure.

Stock

2021-07-30 12:51 | Report Abuse

Today 18kHarmoni Olangbolo and BilisMasin. Same account , all not yet wake up to work. So lazy.

Stock

2021-07-29 17:49 | Report Abuse

@BilisMasin
Yes, yes yes, positive at starting? Check back your comment Liar... Pandai tipu,and take turn comment. Comment almost the same only

Stock

2021-07-29 17:17 | Report Abuse

To all my respective Malays friend. No offence.
My comment is just for 18kHarmoni - If you think that this stock is not suitable for you, you can filter your stock by shariah compliance, no need be a rage keyboard warrior, only making noise and non-sense here. If you want syiok sendiri, you can continue make noise.

Stock

2021-07-29 17:06 | Report Abuse

Syiok sendiri.... Now Chinese Malay Indian pula. @18kH , if you want play racist , go back to your zaman. This is new era.

Stock

2021-07-29 16:43 | Report Abuse

Four leg creatures that bark all time. Down the bark louder, up they also bark. No bark No KPI.
Look at their comment, you know they are same person

18KHarmoni

Olangbolo

BilisMasin

Stock

2021-07-29 13:03 | Report Abuse

All time spammer, Everyday main copy paste and take turn comment.
So hard working to cuci forum , a bit pork here, pork there, family here family there.
What a blessing spammer.

18KHarmoni

BilisMasin

olangbolo

Stock
Stock

2021-07-27 16:14 | Report Abuse

I see their whole structure very solid. There are even under coverage of CIDB & SPAN, which is high chance to award project too

Stock

2021-07-27 16:12 | Report Abuse

Any idea what is the rough figure that Sung master can make it in 2021?

Stock

2021-07-27 14:59 | Report Abuse

back to balance now.

Stock

2021-07-27 14:35 | Report Abuse

well, let said no movement atleast coming QR should be better.

Stock

2021-07-27 14:30 | Report Abuse

PROPOSED ACQUISITION BY KANGER OF 1,020,000 ORDINARY SHARES OF SUNG MASTER HOLDINGS SDN. BHD. ("SUNG MASTER"), REPRESENTING 51.0% EQUITY INTEREST IN SUNG MASTER, FOR A PURCHASE CONSIDERATION OF RM94,789,436 TO BE SATISFIED VIA A COMBINATION OF CASH PAYMENT OF RM51,999,999.62 AND THE REMAINING PURCHASE CONSIDERATION OF RM42,789,436.38 TO BE SATISFIED VIA AN ISSUANCE AND ALLOTMENT OF 713,157,273 NEW ORDINARY SHARES OF KANGER ("KANGER SHARE(S)") AT THE ISSUE PRICE OF RM0.06 PER KANGER SHARE

35 agree, 5 againts

PROPOSED SUBSCRIPTION OF 769,513,179 NEW KANGER SHARES ("SUBSCRIPTION SHARE(S)") AT THE SUBSCRIPTION PRICE OF RM0.06 PER SUBSCRIPTION SHARE BY MR. KUAH CHOON CHING

32 agree, 7 against.

PRICE will up later

Stock
Stock

2021-07-27 14:13 | Report Abuse

Guess at least the engine will boots a bit later. Anyhow is good news also. Coming QR should be something sound better.

Stock

2021-07-27 14:06 | Report Abuse

Ini kalilah !

Kanger Executive Director, Mr. Steven Kuah Choon Ching (柯 俊 敬) said that the acquisition of Sung Master represents a significant step in the Group’s strategic plans to develop new income streams that are complementary to Kanger’s recent diversification into the property related and construction business segments.

Bamboo Construction Vaccine...More to come~~~

Stock

2021-07-27 09:52 | Report Abuse

Hidden Gem

Stock

2021-07-27 09:51 | Report Abuse

Hmmm, so what is it ?

Stock

2021-07-27 09:51 | Report Abuse

从事精密工程和精密注塑服务的 YBS International Bhd 表示,其截至 2021 年 3 月 31 日(21 财年)的财政年度的年报将在一个月后,即 8 月 31 日发布。它表示,延期发布其 21 财年年度报告的时间是由于其服务提供商的运营中断,即分发其年度报告的打印机和邮寄者,以及有待服务提供商参与其虚拟年度股东大会.

Stock

2021-07-27 09:50 | Report Abuse

由于长期封锁,合顺控股有限公司预计合顺丰田汽车 (UMWT) 和 Perodua 7 月份的销售额将降至最低。该集团在今天的一份声明中表示,正在进行的全面运动控制令 3.0 对国内汽车行业产生了不利影响,6 月份仅售出 1,921 辆。

Stock

2021-07-27 09:49 | Report Abuse

机电工程服务供应商 Kejuruteraan Asastera Bhd (KAB) 的全资子公司 KAB Smart Solar Energy Sdn Bhd (KSSE) 已收到 Mydin Wholesale Emporium Sdn Bhd 的授标函 (LoA),并与FT Hose & Hose Sdn Bhd 将安装总计 4,971 千瓦峰值 (kWp) 的太阳能系统。 KAB 在今天的一份声明中表示,Mydin Wholesale Emporium 的 LoA 涉及为吉兰丹的 Mydin Mall Tunjong 安装估计容量为 4,000 kWp 的并网光伏太阳能系统。

Stock

2021-07-26 16:53 | Report Abuse

COLOMBO, July 20 (Xinhua) -- Researchers from one of Sri Lanka's leading universities, the Sri Jayewardenepura University, have found that China's Sinopharm COVID-19 vaccine is highly efficient against the Delta variant which has become the dominant variant across the world.

"This vaccine was found very effective for the Delta variant as well. The antibody responses to delta variant and neutralizing antibodies were similar to levels seen following natural infection," the University said on its website on Monday.

According to the study, 95 percent of individuals who received two doses of the Sinopharm vaccine have developed antibodies similar to a naturally infected COVID-19 person.

The study showed that two doses of Sinopharm vaccine produced neutralizing antibodies in 81.25 percent of recipients and that these antibody levels were similar to what would occur after surviving a natural infection of COVID-19.

The research team included Sri Lankan scientists Prof. Neelika Malavige, head of the Immunology and Molecular Medicine Department of the Sri Jayewardenepura University, her colleague Dr. Chandima Jeewandara and Oxford University researchers Prof. Graham Ogg and Prof. Alain Townsend.

Prof. Neelika told Xinhua that Sinopharm is the most used vaccine being rolled out in Sri Lanka presently due to the availability of stocks in the country.

To date, 4.63 million people in Sri Lanka have received the first dose of Sinopharm COVID-19 vaccine, and 1.29 million others had received the second dose of the vaccine. No single severe side effect case relevant to the vaccine has been reported.

Prof. Malavige said this study is the first of its kind to be published in the world and experts looked at every possible angle of the immune system from the Sinopharm jab.

The vaccine was also compared to the Alpha and Beta variants of the virus as well as the original virus.

"The conclusion of this report is that when it comes to Delta and other variants, the Sinopharm vaccine induces similar levels of antibody responses as people who have naturally been infected, Which is very good," Prof. Malavige said.

"Between the age groups of 20 to 40, 98 percent developed antibodies while in the age group of over 60, 93 percent developed antibodies. This is not surprising as older people respond less to vaccines," the Professor added.

She said this data on the Sinopharm did not turn up to the world before, and such real-world data was important to build up vaccine confidence domestically and internationally. Enditem

Stock

2021-07-26 16:48 | Report Abuse

Kanger more to go !!!

Stock
Stock

2021-07-19 17:13 | Report Abuse

Goreng goreng and invest long term different story.
Basically 18k & BilisMasin bodog bodog xtau what is goreng goreng.
Only know know to mislead.

Stock

2021-07-19 16:36 | Report Abuse

Started to go green. Time to goreng goreng

Stock

2021-07-19 16:13 | Report Abuse

Tq Ctos, profit took.

Stock

2021-07-19 16:12 | Report Abuse

Thanks for the info DingHai888

Stock

2021-07-19 15:32 | Report Abuse

Everyone have a look, this two account, like crazy peoples, news fake. Announcement fake.
Everything fake, every their brain i guess. haahah, what A joker.

BilisMasin
18KHarmoni

Stock

2021-07-19 15:23 | Report Abuse

Probably there are co-op behind there, or something big is brewing behind kanger.

Stock
Stock
Stock
Stock

2021-07-15 11:06 | Report Abuse

Kanger starting to start, Is time for Kanger now. Ez Money, Thanks Kanger

Stock

2021-07-14 16:35 | Report Abuse

KUALA LUMPUR: Selangor recorded the lowest vaccination rate as compared to other states in a 10-day period, despite registering a high number of Covid-19 fatalities.

Selangor Taskforce for Covid-19 chairman Datuk Seri Dr Dzulkefly Ahmad said he was disappointed with the vaccination rate in the state under the Covid-19 National Immunisation Programme (NIP).

"After 24 days since I posted my tweet on May 28, observe the distribution of vaccines, registration and mortality percentage within 10 days in Selangor and other (states).

"Selangor is the lowest despite the Sultan of Selangor, Sultan Sharafuddin Idris Shah, expressing his disappointment and disapproval over the Covid-19 Immunisation Task Force (CITF) on June 7," he said on Twitter today.

MORE NEWS
1,529 new Covid-19 cases today, lowest daily tally this year
Covid-19: 2,468 new cases, 14 fatalities today
Selangor's Covid-19 infection rate increases
Comparing vaccine efficacy is like comparing apples to oranges
According to the graphic posted by Dr Dzulkely, only 17.15 per cent of those in Selangor registered under the NIP had been inoculated as compared to the 34.94 per cent of deaths recorded in the state over the last 10 days, as of June 20.


He said Selangor has the lowest number of people being vaccinated, while also topping the Covid-19 fatalities list as compared to other states.